Bedrijf laden
Just reported
Q3 2026 results
From Emergent Biosolutions's results release of 2 november 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 110M
-52% y/y
-53% q/qGuided
US$ 120M
midpoint
Within guide-8,3%EPS, GAAP
Actual
US$ -0,64
Guided
—
No guide given
Operating income, GAAP
Actual
US$ -37,3M
Guided
—
No guide given
Company outlook
Full year 2026
- RevenueUS$ 600M – US$ 645M-16% y/y Lowered -5,7%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Emergent Biosolutions is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$ 33,5BA
NBIXNeurocrine Biosciences, Inc.US$ 17,6BA+
ELANElanco Animal Health IncorporatedUS$ 13,2BA
KNSAKiniksa Pharmaceuticals International, plcUS$ 8,1BA+
LQDALiquidia CorporationUS$ 5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A
Gebouwd uit de eigen deponeringen van Emergent Biosolutions Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
